Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, announced today the addition of Stephanie H. Astrow, Ph.D., as the Company’s Vice President for Research and Development. In her role, Dr. Astrow will be responsible for leading the company’s research and development programs, as well as identifying and incorporating new technologies into the services that the Company provides to the medical community.
“With her strong background in the oncology molecular diagnostics industry we believe Stephanie is the perfect fit to lead our R&D efforts,” said Thomas Bologna, Chairman and Chief Executive Officer of Response Genetics. “Stephanie’s track record of identifying and developing biomarker assays and driving scientific innovation to expand business will be a tremendous asset to us and we are looking forward to her contributions.”
Dr. Astrow brings extensive experience in molecular diagnostics research and development as well as operational experience to her role at Response Genetics. Most recently, Dr. Astrow was Scientific Director for Oncology at Quest Diagnostics, the largest global provider of diagnostic testing. At Quest, she played a key role in expanding business by introducing new assays and services, as well as coordinating development strategy for companion diagnostics with key pharmaceutical companies. Prior to her work at Quest, Dr. Astrow served as Vice President and Director of Oncology at Pathway Diagnostics, and Vice President, Scientific Director of Impath, Inc. Dr. Astrow received a Bachelor of Arts in Biology and Medicine at Brown University, and her Ph.D. in Molecular and Cell Biology from the University of California, Berkeley. She also holds a Masters of Business Administration from Pepperdine University.
Dr. Astrow, commenting on her appointment said, “I couldn’t be more excited to be joining Response Genetics, a company that matches my background and interests very well. I look forward to putting my skills and experience to work in helping people with cancer, and being part of a company that is both patient-centric and well suited to prosper in the exciting field of personalized diagnostics.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV